Business Context and Reporting Period
Acurx Pharmaceuticals, Inc. (ACXP) is a clinical-stage biopharmaceutical company focused on developing a novel class of antibiotics targeting Gram-positive bacteria, with its lead candidate, ibezapolstat, in development for Clostridioides difficile infections (CDI). This Form 10-Q covers the quarterly period ended June 30, 2026. The Company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,935,155) | $(4,395,472) |
| Operating Expenses | $4,023,219 | $4,446,165 |
| Research & Development (R&D) | $1,413,004 | $1,123,009 |
| General & Administrative (G&A) | $2,610,215 | $3,323,156 |
| Cash and Cash Equivalents (End of Period) | $10,656,386 | $6,064,128 |
| Net Cash Used in Operating Activities | $(3,117,485) | $(3,722,073) |
| Net Cash Provided by Financing Activities | $6,217,771 | $6,079,488 |
| Total Liabilities | $2,832,746 | $2,420,943 |
| Shareholders' Equity | $8,152,031 | $3,566,331 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $0.46 million (10%) compared to the prior year period, primarily driven by a reduction in General and Administrative expenses.
- Expense Trends: R&D expenses increased by 26% ($0.29 million) due to costs associated with a new recurrent CDI trial program and manufacturing. G&A expenses decreased by 21% ($0.71 million) due to lower professional, legal, and share-based compensation costs.
- Liquidity Improvement: Cash balances increased by approximately $3.1 million during the period, resulting from net proceeds from financing activities exceeding operating cash burn.
- Capital Structure: The Company completed a 1-for-20 reverse stock split in August 2025 (reflected retrospectively) and increased authorized common stock to 250 million shares.
Guidance, Outlook, and Risks
- Clinical Progress: The Company announced a new clinical development initiative for recurrent CDI (rCDI) in March 2026, with an open-label pilot trial expected to enroll up to 20 patients. First patient enrollment is anticipated in the fourth quarter of 2026.
- Financing Activities: The Company raised approximately $6.2 million in net cash during the six months ended June 30, 2026, through an Equity Line of Credit (ELOC) with Lincoln Park Capital and a Registered Direct Offering in April 2026.
- Going Concern: Management states that current cash resources ($10.7 million) are not sufficient to meet anticipated cash requirements for at least 12 months from the issuance date. The Company expects to continue incurring losses and will need additional equity financing or grant funding to sustain operations.
- Listing Risks: The Company previously regained compliance with Nasdaq minimum bid price and stockholders' equity requirements following the reverse stock split. However, new SEC-approved Nasdaq rules requiring a Market Value of Listed Securities (MVLS) of at least $5 million were stayed by the SEC on July 29, 2026, pending further review.
- Forward-Looking Statements: The filing contains significant risks regarding the ability to obtain regulatory approval for ibezapolstat, commercialize products, and secure future funding.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next financing round given the "substantial doubt" regarding the ability to continue as a going concern.
- ELOC Utilization: Confirm the remaining capacity under the $12.0 million Lincoln Park ELOC and the terms of future drawdowns.
- Clinical Trial Enrollment: Monitor the start date and enrollment progress of the new recurrent CDI pilot trial announced for Q4 2026.
- Nasdaq Compliance: Track the status of the stayed $5 million MVLS requirement and the Company's market capitalization relative to this threshold.
- Dilution Impact: Assess the dilution effect from the April 2026 Registered Direct Offering and ongoing ELOC issuances on existing shareholders.